Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Sponsor
University of Erlangen-Nürnberg Medical School
Study ID
NCT02471963
Phase
PHASE3
Status
Completed

Conditions

  • Diabetes Mellitus Type 2

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Empagliflozin may lead to improved vascular and endothelial function in the macro- (pulse wave reflection) and microcirculation (retinal circulation) and improve cardiovascular risk factors, imparticular by effectively controlling hyperglycemia, arterial hypertension and obesity.

Key Dates

Start date
Dec 31, 2014
Status verified
May 2018
Primary completion
Nov 30, 2015
Completion
Jun 30, 2016

Study Design

Enrollment
74 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Empagliflozin
    Empagliflozin, 25 mg/day, oral administration, 6 weeks
  • Placebo Comparator: Placebo
    Placebo, oral administration, 6 weeks

Primary Outcome Measure

Effect of empagliflozin after 6 weeks of treatment on macrocirculation [ Time Frame: 6 weeks ]

Related Studies